title: Combination of Vasopressin -Epinephrine as a Novel Candidate in Patients with Cardiac Arrest.
abstract: OBJECTIVE
  Out-hospital Cardiac arrest is considered as a global disease, which causes high rate of morbidity and mortality. Although, the return of spontaneous circulation occurs in 10 to 60 percent of cases in OHCA, with variety of treatment, the most patients faced with multiple organ failure and ultimately death. The investigations demonstrated that endogenous vasopressin levels in patients with successful resuscitation is more than died patients. Therefore, it seems the administration of vasopressin during cardiopulmonary resuscitation could be useful. The current study aimed to investigate the administration of vasopressin and epinephrine on neurological surviving of cardiac-respiratory arrest via evaluation of S100b serum factor.
  
  
  METHODS
  For this reasons, after collecting of sera from two vasopressin-epinephrine and epinephrine receiving patients, sera were subjected for ELISA to evaluate S100b.
  
  
  RESULTS
  The findings demonstrated that the great reductions of S100b in sera of patients that receiving vasopressinepinephrine in comparison with those patients that only got the epinephrine. Although no significant difference was observed between two groups, but survival rates after hospital discharge in group that receiving vasopressin-epinephrine was significantly higher than those patients that only got only epinephrine.
  
  
  CONCLUSIONS
  Today, no advantages of vasopressin over epinephrine have been observed in clinical trials and more studies needed to improve the OHAC patient's surveillance. But, The combination vasopressin-epinephrine in the current study demonstrated that efficacy of this combination should be noted.
authors.forename: Nasim
authors.initials: N
authors.lastname: Ghafourian
authors.forename: Nader H
authors.initials: NH
authors.lastname: Maniae
authors.forename: Morovat
authors.initials: M
authors.lastname: Taherikalani
authors.forename: Maryam
authors.initials: M
authors.lastname: Mehrazi
authors.forename: Mahnaz
authors.initials: M
authors.lastname: Hossieni
authors.forename: Firouzeh
authors.initials: F
authors.lastname: Valian
authors.forename: Shahriar
authors.initials: S
authors.lastname: Karami
authors.forename: Yazdan
authors.initials: Y
authors.lastname: Rahmatian
authors.affiliation: M.D. Department of Emergency Medicine, Iran University of Medical Sciences, Tehran, Iran. tavakoli.n@iums.ac.ir.
authors.forename: Nader
authors.initials: N
authors.lastname: Tavakoli
mesh_terms: D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D004837:Epinephrine / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058687:Out-of-Hospital Cardiac Arrest / Q000188:drug therapy* / Q000401:mortality; D064568:S100 Calcium Binding Protein beta Subunit / Q000097:blood; D015996:Survival Rate; D014662:Vasoconstrictor Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D014667:Vasopressins / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D064568:S100 Calcium Binding Protein beta Subunit; C579160:S100B protein, human; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D004837:Epinephrine